Uncontrolled hypertension and the emerging role of aldosterone synthase inhibition: a world-first case report

Resistant hypertension remains a major therapeutic challenge and is associated with substantially increased cardiovascular and renal morbidity and mortality. Excess aldosterone activity plays a central role in the pathophysiology of resistant hypertension through sodium retention, vascular remodeling, endothelial dysfunction, and sympathetic activation. Although mineralocorticoid receptor antagonists (MRAs) such as spironolactone are established fourth-line therapies, many patients remain inadequately controlled. Baxdrostat, a highly selective aldosterone synthase inhibitor, represents a novel therapeutic strategy that directly suppresses aldosterone production upstream in the renin–angiotensin–aldosterone system (RAAS). We report the case of a 55-year-old man with multiple cardiovascular comorbidities and persistent resistant hypertension despite comprehensive optimization of conventional antihypertensive therapy, including spironolactone. Following initiation and dose escalation of baxdrostat, clinically meaningful blood pressure reduction was achieved without adverse effects or biochemical abnormalities. This case highlights the potential role of aldosterone synthase inhibition in patients with persistent hypertension despite contemporary guideline-directed medical therapy.